Ovreena®


  • Contains 30 mcg ethinylestradiol and 150 mcg levonorgestrel, exactly the same active ingredients as Ovranette® 1,2
  • Indicated for the prevention of pregnancy in women who elect to use oral contraception
  • Side effects may include mood changes and depression.
  • Causes changes in the endometrium and cervical mucus1,2
  • Reliable, highly effective and well tolerated oral contraceptive when taken correctly1
  • OVREENA® has a Pearl Index of 0.43
  • OVREENA® is GMS Reimbursed

OVREENA®  is suitable for use in the following patient groups:4,5

  • Women on the GMS reimbursement scheme
  • Women who want autonomy and control over their menstrual cycle
  • Women aged up to 50 years with no other medical conditions
  • Women ≥6 months postpartum if fully breast feeding
  • Women ≥6 weeks postpartum if not breast feeding
  • Women with dysmenorrhoea who have an irregular, heavy or prolonged bleeding pattern
  • Women with endometriosis
SPC

Patient Information Leaflet
Report an adverse event

References:

1. Ovreena® SPC
2. Ovranette® SPC available at www.medicines.ie
3. Faculty of Sexual and Reproductive Health Care (FSRH). First Prescription of Combined Oral Contraception. Clinical Effectiveness Unit July 2006 (Updated January 2007) London: FSRH, 2007.
4. Faculty of Sexual and Reproductive Health Care (FSRH). UK Medical Eligibility Criteria for Contraceptive Use. UKMEC 2016. London: FSRH, 2016.
5. WHO Guidelines. Medical Eligibility Criteria for contraceptive use 2015 update

If you have a medical query about a Consilient Health medicine, please contact Consilient Health at drugsafety@consilienthealth.com or +353 (0)1 2057766.

For all other queries, please contact our Irish office at Tel: +353 (0)1 2057760, Fax: +353 (0)1 2698919 or irishoffice@consilienthealth.com

Copyright ©2015 Consilient Health Ltd. All rights reserved. The information on this website is intended for healthcare professionals registered in the Republic of Ireland only.

IE/OCS/0817/0058e(1)(1) Date of preparation: June 2021